Press Release

Digbi Health in the news

Featured Press

pin

Digbi Health Announces Significant Healthcare Cost Savings for Employers Using Its Precision Biology Platform to manage GLP-1, Metabolic, and GI costs.

Peer-reviewed actuarial claims analysis confirms up to 9X ROI, demonstrating the power of gut microbiome and genetics-based care. MOUNTAIN VIEW, Calif. — December 19, 2025— Digbi Health, the pioneer of Precision Biology–based chronic care, today announced actuarially validated healthcare cost savings for employers, supported by a newly published, multi-year medical claims analysis in the peer-reviewed journal Healthcare. The analysis confirms that employers using Digbi Health’s Precision Biology platform achieved actuarially guaranteed, hard-dollar reductions in medical claims, driven by lower pharmaceutical utilization and reduced inpatient and outpatient costs. These savings were achieved by treating five chronic conditions — obesity, metabolic, gastrointestinal, mental health, and auto-immune — on a single platform, informed by genetic insights, gut microbiome analysis, and more than 8,000 biomarkers. This announcement marks a critical milestone for digital health, an industry that has historically relied on “soft” and “vibe” ROI metrics such as engagement, while struggling to demonstrate direct medical cost reduction. Validated Cost Savings by Condition The peer-reviewed claims analysis evaluated multiple years of medical spend across seven U.S. self-insured employers, comparing Digbi Health participants with matched non-participants. The study identified significant reductions in medical claims, including: Digestive and GI cost reduction: - $9,240+ per member per year  Obesity-related medical cost reduction: -  $4,884+ per member per year Anxiety-related medical cost reduction : - $1,356+ per member per year  Overall medical spend Reduction: -$3,012 per member per year  Precision Biology as the New Standard of Care While most high-cost claimants are polychronic, traditional digital care programs treat these conditions in silos, resulting in fragmented care, poor engagement, overlapping medications, and escalating costs. Digbi Health's Precision Biology platform targets the root cause of biological and behavioral changes by analyzing biomarkers from the gut microbiome, blood, and genetic tests, along with dietary intake, to treat multiple conditions simultaneously — replacing fragmented point solutions with a single, coordinated system of care. "More than 100 employers are already using Digbi Health to manage 70% of their healthcare controllable costs driven by GLP-1s, obesity, metabolic, and GI conditions. Precision Biology is no longer the future of care — it is the new standard,” said Ranjan Sinha, Founder and CEO of Digbi Health.“Just as we pioneered Precision Biology in chronic care, we are now showing leadership in proving that root-cause treatment can materially reduce medical claims across multiple conditions and clean up the point solutions proliferation.” Extending Savings in the GLP Era Digbi Health continues to expand its GLP-1 offering to include direct-to-employer and employee cash pay fulfillment options, while supporting PBM and 340B medication access. By combining GLP-1 therapy with biologically personalized support, Digbi Health achieves significant reductions in GLP-1 adverse effects, thereby improving adherence and weight loss outcomes, and further extending the medical savings demonstrated in the claims analysis. About Digbi Health Our mission is to end the scourge of food-related chronic illness - obesity, metabolic, digestive, autoimmune, and mental health - for this and future generations to advance human longevity. Digbi combines thousands of genetics, gut microbiome, CGM, blood biomarkers, and AI-powered insights to deliver personalized, nutrition-first care solutions to prevent and treat obesity, metabolic, and gastrointestinal issues in 40 languages. Digbi is committed to making personalized care universally accessible to individuals through their employers, insurance-covered plans, and Medicare, creating personalized, proactive, predictive, data-driven, and home-based care that turns food from a cause of illness into a means of medicine.  With over 100 employers offering Digbi Health, Precision Biology isn't the future of care. It's the New Standard.  

Aniiket Sengar
18 December, 2025
pin

Digbi Health Expands its Multi-Condition Care Platform to Enhance Tolerability and Efficacy of GLP-1 Drugs

The first Precision Biology-based GLP-1 companion program, Digbi Care (™), gets even better by incorporating gut microbiome and genetic biomarkers that determine tolerability and efficacy of GLP-1 drugs.    PALO ALTO, California.  News Provided by Digbi HealthDigbi Health, the leader in Precision Biology care, is advancing obesity management with groundbreaking enhancements to GLP-Compass (™), its  GLP-1 telehealth program. Digbi Health introduced an advanced obesity test that includes genetic, blood glucose, gut microbiome biomarkers, and clinical GI helath assessment components to personalize nutritional and pharmacotherapy support, ensuring everyone receives the right care based on their biology and lifestyle. Understanding the Different Causes of Obesity to Personalize Treatment The causes of obesity, efficacy, and tolerability of GLP-1 medication vary widely among individuals based on their genetics, gut microbiome, and glucose metabolism. For some, obesity is primarily driven by insulin-related metabolic issues. For others, it stems from dysfunction of the gut-brain axis, which influences cravings and hunger regulation, as well as GLP-1 side effects such as nausea and diarrhea. By isolating these different profiles, Digbi Health can tailor treatment  more precisely, leading to 3X better weight loss outcomes and 5X better drug tolerability than traditional one-size-fits-all GLP-1 lifestyle companion programs, which ignore the patient's biology, ethnicity, and gender. Building Innovation: The First Precision Biology-Based Obesity Test Following the successful launch of its GLP Compass(™), Digbi Health continues to innovate by expanding its obesity test capabilities in 2025. GLP Compass(™) provides members with clarity on their weight loss journey by determining who truly needs GLP-1 drugs versus those who can achieve sustainable weight loss through food-as-medicine. This ensures that patients avoid unnecessary medication, while employers and health plans incur fewer costs, and natural and sustainable health improvements are maximized. 2025 Expansions: GLP-1 Drug Responsiveness Prediction – Research indicates that 25% of individuals on GLP-1 drugs experience a weight loss of less than 5%, while 25% experience a weight loss of more than 15%. By analyzing glucose metabolism, genetic predispositions, and individual gut microbiome, this test predicts drug responsiveness and optimizes treatment modalities to ensure a uniform and effective response across individuals. GI Adverse Effect Risk Assessment—40% of patients on GLP-1 drugs discontinue the medication. Gastrointestinal adverse effects are the primary cause of discontinuation. The test enables the Digbi care team to anticipate and manage gastrointestinal side effects that commonly occur with GLP-1 medications. By anticipating risk factors, patients can work with the AI-supported Digbi care team to proactively manage nausea, abdominal flare-ups, and improve adherence, ultimately enhancing overall success with the therapy. GLP-1 Tapering Success Predictor—This first-of-its-kind tool identifies members who are ideal candidates for tapering or dose reduction based on over 150 parameters across lifestyle, genetics, and gut health. This ensures that members who taper off the drug maintain their weight long-term without GLP support. Digbi developed GLP Compass using AI and millions of data points from the biology, food, medical, and lifestyle data of 10,000 patients over a 52-week period. It sets a new standard in obesity management and optimizing pharmacotherapy. "Our goal is to provide personalized and AI-based nutrition-first care for the top food-related illnesses—Obesity, Type 2 diabetes, gastrointestinal disorders, and mental health," said Ranjan Sinha, Founder and CEO at Digbi Health. "By expanding our industry-leading obesity test, we reinforce our commitment to innovation and safety-first AI-based care." About Digbi HealthDigbi is the first company to offer precision biology-based care to over 25 million people across eight health plans and large to medium-sized employers, all supported by food-as-medicine and a national telehealth clinic specializing in obesity, cardiometabolic, and gastrointestinal health.  Digbi combines thousands of genetics, gut microbiome, CGM, blood biomarkers, and AI-powered insights to deliver personalized, nutrition-first care solutions to prevent and treat obesity, metabolic, and gastrointestinal issues in 40 languages. Precision Biology is no longer the future of care. With +100 employers using Digbi Health, it's the new standard.Contact:Aniiket Sengar VP Marketing Operationsaniiket@digbihealth.com

Ranjan Sinha
09 December, 2025
pin

Digbi Health Expands Its Employer Offering with the GLP-1 Obesity Management Solution Integrated Across Payer, PBM, Provider, and Employer

News Provided by Digbi Health Dec 1 2025 10:00 EST State Public Health Insurance Trust Partners with Digbi Health to Manage Obesity Treatment Costs Amid Rising GLP-1 Drug Expenses for its Municipal and Teachers Union Workers Mountain View, July 22, 2024 – A leading public health insurance trust has selected Digbi Health to manage the escalating costs and effective utilization of new GLP-1 weight-loss drugs. This partnership will leverage Digbi Health's proprietary Obesity Compass to provide effective and cost-efficient treatment plans for all its members. Due to the surge in demand for GLP-1 drugs, employers and health plans nationwide face uncertainty and significant cost increases. This partnership addresses these challenges by employing innovative solutions without compromising a member’s health. Key Highlights: Effective Cost Management:The initiative launched in June as a cost-containment strategy after unsustainable growth in GLP-1 medication usage and costs. Prior Authorization:Digbi Health will oversee the Prior Authorization for all weight management medications, using patented predictive modeling to determine the most effective and economical care modalities for members to achieve a healthy BMI. Holistic Solution: Digbi Health leverages genetics, gut microbiome, continuous glucose monitoring (CGM), and lab reports to provide personalized food and lifestyle support to all members on weight management medications. This approach addresses the underlying root causes of their conditions, related comorbidities, medication side effects, and, if recommended, medication tapering. Precision Biology is an innovative approach that uses an individual's genetic makeup, gut microbiome profile, and metabolic data to create highly personalized treatment plans. Precision Biology can identify the most effective dietary, lifestyle, and pharmacological interventions by analyzing a person's unique biological data. This method ensures that treatments are tailored to address the root causes of obesity and related conditions, resulting in more effective and sustainable health outcomes. “As the market struggles with finding an optimal strategy for weight management and GLP-1 cost containment, we aim to set new care standards by focusing on three key areas: enhancing member experiences through integrations, using Precision Biology to more accurately identify those who need medication support, and tackling the underlying root causes, comorbidities, and side effects. We look forward to successfully collaborating with employers, health plans, benefits consultants, and PBMs to deliver personalized, effective, and affordable care,” said Ranjan Sinha, Founder and CEO of Digbi Health. About Digbi Health: Digbi Health pioneered Precision Biology to treat obesity, T2 Diabetes, and digestive health by harnessing genetics and gut microbiome analysis. This innovative approach develops personalized "Food-As-Medicine" treatment plans, targeting the root causes of obesity and T2D. Digbi Health’s GLP Compass, developed working with Novo Nordisk and the University of Virginia Medical School, uses proprietary data and AI models to identify the most clinically effective and cost-efficient treatment paths.

Aniiket Sengar
01 December, 2025

Latest Press

Digbi Health Announces Significant Healthcare Cost Savings for Employers Using Its Precision Biology Platform to manage GLP-1, Metabolic, and GI costs.

Peer-reviewed actuarial claims analysis confirms up to 9X ROI, demonstrating the power of gut microbiome and genetics-based care. MOUNTAIN VIEW, Calif. — December 19, 2025— Digbi Health, the pioneer of Precision Biology–based chronic care, today announced actuarially validated healthcare cost savings for employers, supported by a newly published, multi-year medical claims analysis in the peer-reviewed journal Healthcare. The analysis confirms that employers using Digbi Health’s Precision Biology platform achieved actuarially guaranteed, hard-dollar reductions in medical claims, driven by lower pharmaceutical utilization and reduced inpatient and outpatient costs. These savings were achieved by treating five chronic conditions — obesity, metabolic, gastrointestinal, mental health, and auto-immune — on a single platform, informed by genetic insights, gut microbiome analysis, and more than 8,000 biomarkers. This announcement marks a critical milestone for digital health, an industry that has historically relied on “soft” and “vibe” ROI metrics such as engagement, while struggling to demonstrate direct medical cost reduction. Validated Cost Savings by Condition The peer-reviewed claims analysis evaluated multiple years of medical spend across seven U.S. self-insured employers, comparing Digbi Health participants with matched non-participants. The study identified significant reductions in medical claims, including: Digestive and GI cost reduction: - $9,240+ per member per year  Obesity-related medical cost reduction: -  $4,884+ per member per year Anxiety-related medical cost reduction : - $1,356+ per member per year  Overall medical spend Reduction: -$3,012 per member per year  Precision Biology as the New Standard of Care While most high-cost claimants are polychronic, traditional digital care programs treat these conditions in silos, resulting in fragmented care, poor engagement, overlapping medications, and escalating costs. Digbi Health's Precision Biology platform targets the root cause of biological and behavioral changes by analyzing biomarkers from the gut microbiome, blood, and genetic tests, along with dietary intake, to treat multiple conditions simultaneously — replacing fragmented point solutions with a single, coordinated system of care. "More than 100 employers are already using Digbi Health to manage 70% of their healthcare controllable costs driven by GLP-1s, obesity, metabolic, and GI conditions. Precision Biology is no longer the future of care — it is the new standard,” said Ranjan Sinha, Founder and CEO of Digbi Health.“Just as we pioneered Precision Biology in chronic care, we are now showing leadership in proving that root-cause treatment can materially reduce medical claims across multiple conditions and clean up the point solutions proliferation.” Extending Savings in the GLP Era Digbi Health continues to expand its GLP-1 offering to include direct-to-employer and employee cash pay fulfillment options, while supporting PBM and 340B medication access. By combining GLP-1 therapy with biologically personalized support, Digbi Health achieves significant reductions in GLP-1 adverse effects, thereby improving adherence and weight loss outcomes, and further extending the medical savings demonstrated in the claims analysis. About Digbi Health Our mission is to end the scourge of food-related chronic illness - obesity, metabolic, digestive, autoimmune, and mental health - for this and future generations to advance human longevity. Digbi combines thousands of genetics, gut microbiome, CGM, blood biomarkers, and AI-powered insights to deliver personalized, nutrition-first care solutions to prevent and treat obesity, metabolic, and gastrointestinal issues in 40 languages. Digbi is committed to making personalized care universally accessible to individuals through their employers, insurance-covered plans, and Medicare, creating personalized, proactive, predictive, data-driven, and home-based care that turns food from a cause of illness into a means of medicine.  With over 100 employers offering Digbi Health, Precision Biology isn't the future of care. It's the New Standard.  

Aniiket Sengar
18 December, 2025

Digbi Health Expands its Multi-Condition Care Platform to Enhance Tolerability and Efficacy of GLP-1 Drugs

The first Precision Biology-based GLP-1 companion program, Digbi Care (™), gets even better by incorporating gut microbiome and genetic biomarkers that determine tolerability and efficacy of GLP-1 drugs.    PALO ALTO, California.  News Provided by Digbi HealthDigbi Health, the leader in Precision Biology care, is advancing obesity management with groundbreaking enhancements to GLP-Compass (™), its  GLP-1 telehealth program. Digbi Health introduced an advanced obesity test that includes genetic, blood glucose, gut microbiome biomarkers, and clinical GI helath assessment components to personalize nutritional and pharmacotherapy support, ensuring everyone receives the right care based on their biology and lifestyle. Understanding the Different Causes of Obesity to Personalize Treatment The causes of obesity, efficacy, and tolerability of GLP-1 medication vary widely among individuals based on their genetics, gut microbiome, and glucose metabolism. For some, obesity is primarily driven by insulin-related metabolic issues. For others, it stems from dysfunction of the gut-brain axis, which influences cravings and hunger regulation, as well as GLP-1 side effects such as nausea and diarrhea. By isolating these different profiles, Digbi Health can tailor treatment  more precisely, leading to 3X better weight loss outcomes and 5X better drug tolerability than traditional one-size-fits-all GLP-1 lifestyle companion programs, which ignore the patient's biology, ethnicity, and gender. Building Innovation: The First Precision Biology-Based Obesity Test Following the successful launch of its GLP Compass(™), Digbi Health continues to innovate by expanding its obesity test capabilities in 2025. GLP Compass(™) provides members with clarity on their weight loss journey by determining who truly needs GLP-1 drugs versus those who can achieve sustainable weight loss through food-as-medicine. This ensures that patients avoid unnecessary medication, while employers and health plans incur fewer costs, and natural and sustainable health improvements are maximized. 2025 Expansions: GLP-1 Drug Responsiveness Prediction – Research indicates that 25% of individuals on GLP-1 drugs experience a weight loss of less than 5%, while 25% experience a weight loss of more than 15%. By analyzing glucose metabolism, genetic predispositions, and individual gut microbiome, this test predicts drug responsiveness and optimizes treatment modalities to ensure a uniform and effective response across individuals. GI Adverse Effect Risk Assessment—40% of patients on GLP-1 drugs discontinue the medication. Gastrointestinal adverse effects are the primary cause of discontinuation. The test enables the Digbi care team to anticipate and manage gastrointestinal side effects that commonly occur with GLP-1 medications. By anticipating risk factors, patients can work with the AI-supported Digbi care team to proactively manage nausea, abdominal flare-ups, and improve adherence, ultimately enhancing overall success with the therapy. GLP-1 Tapering Success Predictor—This first-of-its-kind tool identifies members who are ideal candidates for tapering or dose reduction based on over 150 parameters across lifestyle, genetics, and gut health. This ensures that members who taper off the drug maintain their weight long-term without GLP support. Digbi developed GLP Compass using AI and millions of data points from the biology, food, medical, and lifestyle data of 10,000 patients over a 52-week period. It sets a new standard in obesity management and optimizing pharmacotherapy. "Our goal is to provide personalized and AI-based nutrition-first care for the top food-related illnesses—Obesity, Type 2 diabetes, gastrointestinal disorders, and mental health," said Ranjan Sinha, Founder and CEO at Digbi Health. "By expanding our industry-leading obesity test, we reinforce our commitment to innovation and safety-first AI-based care." About Digbi HealthDigbi is the first company to offer precision biology-based care to over 25 million people across eight health plans and large to medium-sized employers, all supported by food-as-medicine and a national telehealth clinic specializing in obesity, cardiometabolic, and gastrointestinal health.  Digbi combines thousands of genetics, gut microbiome, CGM, blood biomarkers, and AI-powered insights to deliver personalized, nutrition-first care solutions to prevent and treat obesity, metabolic, and gastrointestinal issues in 40 languages. Precision Biology is no longer the future of care. With +100 employers using Digbi Health, it's the new standard.Contact:Aniiket Sengar VP Marketing Operationsaniiket@digbihealth.com

Ranjan Sinha
09 December, 2025

Digbi Health Expands Its Employer Offering with the GLP-1 Obesity Management Solution Integrated Across Payer, PBM, Provider, and Employer

News Provided by Digbi Health Dec 1 2025 10:00 EST State Public Health Insurance Trust Partners with Digbi Health to Manage Obesity Treatment Costs Amid Rising GLP-1 Drug Expenses for its Municipal and Teachers Union Workers Mountain View, July 22, 2024 – A leading public health insurance trust has selected Digbi Health to manage the escalating costs and effective utilization of new GLP-1 weight-loss drugs. This partnership will leverage Digbi Health's proprietary Obesity Compass to provide effective and cost-efficient treatment plans for all its members. Due to the surge in demand for GLP-1 drugs, employers and health plans nationwide face uncertainty and significant cost increases. This partnership addresses these challenges by employing innovative solutions without compromising a member’s health. Key Highlights: Effective Cost Management:The initiative launched in June as a cost-containment strategy after unsustainable growth in GLP-1 medication usage and costs. Prior Authorization:Digbi Health will oversee the Prior Authorization for all weight management medications, using patented predictive modeling to determine the most effective and economical care modalities for members to achieve a healthy BMI. Holistic Solution: Digbi Health leverages genetics, gut microbiome, continuous glucose monitoring (CGM), and lab reports to provide personalized food and lifestyle support to all members on weight management medications. This approach addresses the underlying root causes of their conditions, related comorbidities, medication side effects, and, if recommended, medication tapering. Precision Biology is an innovative approach that uses an individual's genetic makeup, gut microbiome profile, and metabolic data to create highly personalized treatment plans. Precision Biology can identify the most effective dietary, lifestyle, and pharmacological interventions by analyzing a person's unique biological data. This method ensures that treatments are tailored to address the root causes of obesity and related conditions, resulting in more effective and sustainable health outcomes. “As the market struggles with finding an optimal strategy for weight management and GLP-1 cost containment, we aim to set new care standards by focusing on three key areas: enhancing member experiences through integrations, using Precision Biology to more accurately identify those who need medication support, and tackling the underlying root causes, comorbidities, and side effects. We look forward to successfully collaborating with employers, health plans, benefits consultants, and PBMs to deliver personalized, effective, and affordable care,” said Ranjan Sinha, Founder and CEO of Digbi Health. About Digbi Health: Digbi Health pioneered Precision Biology to treat obesity, T2 Diabetes, and digestive health by harnessing genetics and gut microbiome analysis. This innovative approach develops personalized "Food-As-Medicine" treatment plans, targeting the root causes of obesity and T2D. Digbi Health’s GLP Compass, developed working with Novo Nordisk and the University of Virginia Medical School, uses proprietary data and AI models to identify the most clinically effective and cost-efficient treatment paths.

Aniiket Sengar
01 December, 2025
Press Release
pin

Digbi Health Expands Its Premier Employer GLP-1 Telehealth Service to Incorporate Self-Pay Access for Employees and Their Family Members

The first precision biology–based telehealth service designed to improve GLP-1 tolerability, safety, and effectiveness is now available as a self-pay option within employer populations.   Mountain View, CA  — Digbi Health today announced the expansion of its nationally deployed employer-sponsored GLP-1 telemedicine program to include a new self-pay access and fulfillment pathway for employees and eligible family members who may not have access to GLP-1 weight-loss medications through their employer-sponsored programs. This expansion makes the first precision biology–powered telehealth service accessible to a broader population within employer ecosystems. Digbi Health’s GLP-1 Program is a comprehensive, employer-backed telemedicine solution—now expanded with a self-pay option—that streamlines every step of the GLP-1 journey for employees and their eligible family members, from clinical evaluation to prescription to fulfillment. Digbi Health’s Precision GLP-1 Program includes: Clinically supervised access to FDA-approved GLP-1 medications, including Wegovy®, Ozempic®, and Zepbound®, with access to an introductory cash price of $199 per month for Ozempic® and Wegovy® injection pens for Digbi self-pay users, along with clear, transparent pricing and no hidden fees. Flexible fulfillment options, including in-pharmacy pickup for Wegovy® or Zepbound® pens and convenient home delivery for Zepbound® vial formulations. Virtual consultations with licensed clinicians who determine eligibility, order all required labs (included at no cost), and write prescriptions when medically appropriate. Continuous clinical oversight to track progress, manage side effects, and adjust titration or care plans to improve tolerability and adherence. Precision biology diagnostics, including DNA testing, gut microbiome testing, and continuous glucose monitoring to identify insulin resistance, glucose dysregulation, and biological factors that influence GLP-1 effectiveness. AI-powered nutritional guidance to optimize protein intake, reduce GI symptoms, improve gut health, and support natural GLP-1 production. A personalized, member-first experience that prioritizes safety, tolerability, and metabolic effectiveness—not just access to medication. The Biology Problem: Why Many GLP-1 Users Quit or Don’t Respond While GLP-1 medications such as Wegovy®, Ozempic®, and Zepbound® have reshaped metabolic health, real-world outcomes remain inconsistent: 30–40% of users experience significant GI-related adverse effects Many experience hair loss, muscle loss, constipation, and nutrient deficiencies Nearly 25% lose less than 5% of their body weight, driven by insulin resistance, impaired glucose control, or microbiome-mediated variability in drug response. These issues drive early discontinuation—creating avoidable waste and limiting long-term outcomes. Digbi Health’s precision-biology approach fills these gaps by addressing the underlying metabolic drivers of GLP-1 tolerability and effectiveness. Every Digbi-covered and Digbi self-pay member receives a fully integrated, biology-driven care model, including: Clinical prescribing and titration pathways for Wegovy®, Ozempic®, and Zepbound® DNA analysis for metabolic risk, appetite regulation, weight regain risk, and drug responsiveness Gut microbiome testing to identify inflammation, digestive vulnerabilities, and GLP-1 degradation pathways Continuous glucose monitoring (CGM) to personalize glucose control and predict medication responsiveness AI-driven meal scoring and nutrition coaching informed by glucose, microbiome, and genetic insights to reduce side effects GI care and food-as-medicine interventions to enhance natural GLP-1 production and improve drug tolerability “GLP-1 tolerability and effectiveness depend heavily on biology. By expanding self-pay access to employees and their families, we ensure that more people receive safe, personalized care—guided by genetics, the microbiome, and glucose data—to improve outcomes and reduce avoidable discontinuation.”— Ranjan Sinha, Founder and CEO,  Digbi Health

Ranjan Sinha
18 November, 2025
pin

Celebrating excellence in health and wellbeing solutions: DIGBI HEALTH selected by Shortlister as a Q3 2025 Top Vendor in Obesity Management, Diabetes Management and GI Health

We’re proud to announce that DIGBI Health has been selected as a Q3 2025 Top Vendor for Weight Management, Diabetes Management, and Digestive Health by Shortlister, the leading marketplace for employers and consultants to find providers in the wellbeing and benefits sector, for ten consecutive quarters. This recognition highlights our mission to bring Precision Biology-based innovation to empower employers in the US and around the world to address the top four food-related illnesses through a food-as-medicine first approach. Our team is dedicated to a person-centered approach to employee health, helping employers consolidate point solutions with a focus on patient-centric care rather than process-centric strategies. As a top vendor for 10 quarters, Shortlister acknowledges our performance in supporting the overall health of employees and organizations, as well as our commitment to customer centricity. Digbi is the first company to provide precision biology-based services to over 25 million people across seven health plans and large to medium-sized employers, all supported by a national virtual clinical network specializing in obesity, cardiometabolic, and gastrointestinal health.Interested in exploring our award-winning services and why employees and consultants consistently rank us as #1 ? Reach out to us at Digbi@digbihealth.com

Ranjan Sinha
27 July, 2025
pin

Gulf Coast Regional Blood Center selects Digbi Health to Elevate Employee Health Programs for Weight Management, Diabetes, and Digestive Issues

Palo Alto, California, Feb 15, 2024 - Digbi Health, an innovator in personalized health technology, is proud to announce its new collaboration with Gulf Coast Regional Blood Center, a key blood provider in Houston and surrounding counties. This partnership is set to revolutionize employee health management by integrating personalized health solutions based on advanced genetics and gut biome analysis into the wellness programs of a critical healthcare provider. Enhancing Employee Wellness at Gulf Coast Regional Blood Center The Gulf Coast Regional Blood Center team will benefit from Digbi Health's comprehensive health platform to optimize weight management and mitigate physical and mental health challenges. By leveraging precision biology through detailed genetics and gut microbiome analysis, this initiative perfectly aligns with the center's dedication to fostering the health and well-being of its employees and the communities they serve. The program specifically addresses chronic conditions such as obesity, type 2 diabetes, and digestive disorders, benefiting employees and their families. A Strategic Collaboration to Enhance Community Health Digbi Health's tailored health approach is strategically aligned with the Gulf Coast Regional Blood Center’s core mission of community partnership to save and sustain lives, beginning with its workforce. This collaboration is poised to enrich the center's employee wellness program, establishing a new benchmark for employee care within the life-saving operations of the blood center. Ranjan Sinha, CEO of Digbi Health, said on the collaboration, "This partnership is a milestone for us at Digbi Health. It embodies our commitment to transform individual chronic care by decoding our genetics, gut biome, and blood markers.“ About Gulf Coast Regional Blood Center Founded in 1975, Gulf Coast Regional Blood Center is an independent, nonprofit organization committed to ensuring a safe and reliable blood supply. With over 650 employees, Gulf Coast Regional Blood Center serves a vast area across Texas, including 26 counties. About Digbi Health Digbi Health specializes in genetics, gut microbiome, and digital health technologies to redefine personalized healthcare. Their platform is designed to reduce medication dependence and healthcare costs, particularly in chronic illness management. For more information, media inquiries, or interviews, please contact: partner@digbihealth.com This contract underscores Digbi Health's commitment to expanding personalized healthcare nationwide.

Aniiket Sengar
15 March, 2024
pin

Digbi Health Launches GLP-Fit™ Program: Expands its Precision Biology Platform to Incorporate GLP-1 based Personalized Care for Obesity

PALO ALTO, Calif., September 28, 2023 – (BUSINESS WIRE)-- Digbi Health, the leader in precision biology-based telehealth care for three of the top four healthcare costs - Obesity, T2D, and Digestive Health - announced today the launch of its latest innovation in obesity care, Digbi GLP-Fit™, a scientifically-backed approach to identify the best treatment path for an individual to prevent and treat obesity.  Key Highlights: Digbi GLP-Fit™  uses the science of precision biology to identify the best treatment path for obesity for an individual with 87% accuracy, which may include 1) only precision nutrition, 2) a combination of precision nutrition and lower-cost drugs like Metformin, or 3) a combination of precision nutrition and GLP-1 medications. For Pharmacy Benefit Managers (PBMs), Digbi GLP-Fit™ streamlines prior authorization processes for GLP-1 obesity management drugs, eliminating member frustration, generating multi-million dollar savings, and creating goodwill for health plans and employers. Digbi GLP-Fit™ program guarantees 100% financial ROI, providing immediate and tangible savings for employers, PBMs, and health plans, all while ensuring optimal and medically safe patient care. The Science Behind Digbi GLP-Fit(™) This clinically proven approach integrates genetics, gut microbiome, and Continuous Glucose Monitoring (CGM) insights to recommend the best path for care and deliver personalized, clinically effective obesity treatment programs. Unlike other digital programs that rely exclusively on behavior change, Digbi GLP-Fit™  is based on recognition by the National Institutes of Health (NIH)  and medical research institutions like Harvard Health that genetics account for up to 80% of the risk of obesity and that an individual's insulin resistance and gut-microbiome are essential factors in addressing obesity. Digbi GLP-Fit™ integrates telehealth and precision nutrition based on genetics, gut microbiome, and insulin metabolism. Sustainable, Effective, and High-Quality Care This personalized approach offers tremendous savings for employers and payers. Digbi's program ensures that individuals are not unnecessarily on lifelong GLP-1 treatments, aligning with Digbi Health's prevention and effective care mission. With a Google rating of 4.8 stars, Digbi Health stands out for its unwavering commitment to delivering a high-quality member experience. "We believe in the power of precision biology and full-spectrum obesity care, which includes anti-obesity medications only when necessary. Recognizing that everyone does not respond the same way to food and medicine, Digbi is committed to making obesity care personalized, preventive, and holistic," said Ranjan Sinha, CEO of Digbi Health. "Payers and employers want to partner with us because our unique approach delivers the best obesity solution that is clinically safe and financially sustainable.” Novo Nordisk's Global Prevention Accelerator Program recently selected Digbi to pilot-test solutions for preventing obesity and related cardiometabolic conditions.   True Personalization: The 5-Point  Digbi GLP-Fit™ Program Difference While other digital providers tout personalization, Digbi GLP-Fit delivers the following advanced capabilities: Precision Diagnostics: Incorporates genetics, gut microbiome, and Continuous Glucose Monitoring (CGM) to provide a comprehensive bio-digital twin view of an individual's health. Risk Assessment: Evaluate the patient's obesity risk embedded in their genetics, gut microbiome, and insulin metabolism. Three hundred gene variants are used to develop and monitor a polygenic risk score for weight regain. Precision Biology-Based  Lifestyle Support: The FDA requires GLP drugs to have nutrition and lifestyle support. Proven and Patented De-prescription Path: Develops clinically safe,  sustainable, personalized tapering off-plan for GLP drugs. Gut Microbiome Informed Care: GLP is a gut hormone that regulates appetite, metabolism, and insulin secretion. Recent studies have shown that the gut microbiome may play a role in the effectiveness of GLP-1 drugs. With Digbi GLP-Fit™, the gut microbiome is monitored every 120 days. A longer tapering period is considered if the gut microbiome has not shifted to a less obesogenic state. Media Contact: Beverly Ibarrolan; beverly@digbihealth.com About Digbi Health Digbi Health is leading through innovation, offering a holistic solution for treating Obesity, Cardiometabolic, and Digestive disorders—three of healthcare's top 4 costly conditions. Our Precision Biology approach uses genetics, gut microbiome, Abbott CGM, and pharmaceuticals only when necessary to create personalized care programs that slash medication dependency and healthcare costs. We are on a mission to make chronic illness optional. Learn more at: www.digbihealth.com  

Ranjan Sinha
29 September, 2023
pin

Digbi Health features in the Top 10 Startups of LG’s ‘Mission for the Future’ challenge

Chosen ‘Mission for the Future’ Companies and LG to Jointly Pursue Innovative Solutions for Digital Health, the Metaverse and Electric Mobility. The LG Electronics North American Innovation Center, LG NOVA, has selected the Finalist companies for its Mission for the Future global challenge program. Representing multiple potential business paths in three industries, the companies will be working with the LG NOVA team to collaborate on new business ventures, alongside continuing to grow and scale their companies, qualifying for potential investment from LG and other investors within LG NOVA ecosystem to develop impactful solutions for people, communities and the planet.* “This inaugural year of our challenge demonstrated how effective and powerful collaboration between technology startups and established corporations can help accelerate the innovation process,” said LG Electronics Senior Vice President of Innovation Dr. Sokwoo Rhee and head of LG NOVA. “Congratulations to the Finalists and all the companies that participated in the Mission for the Future challenge. We look forward to the journey with these companies innovating for a brighter, more technologically advanced future.” The finalists were selected from an initial pool of approximately 1,300 applicants. They secured the top spot after working closely with the LG NOVA Entrepreneur-In-Residence team over a six- to nine-month period to build and test the proposals. Throughout the process, the companies had opportunities to meet with LG business teams and other investors within the LG NOVA ecosystem. Finalists were presented to LG Electronics Global CEO William Cho. This unique challenge program, which has the opportunity to diversify and expand LG’s technology portfolio, prioritizes innovating for a better life across key impact industries, according to Rhee. “These incredible companies hold the potential of changing the world, and LG looks forward to collaborating with them to leverage innovation to impact society in meaningful ways,” he said. With this selection of companies, LG NOVA will build new businesses in Digital Health, Electric Mobility and the Metaverse and pursue multiple paths to deliver new services and solutions that will help us move forward faster into the future. Digital Health – With digital health capabilities key to enabling the delivery of healthcare to diverse and disparate communities, LG NOVA is working to expand and scale greater access to healthcare and personal health services. Digbi Health: is a digital care platform to prevent and reverse chronic metabolic, digestive and mental health conditions using gut microbiome insight, genetics, AI and food-as-medicine. Together LG and Digbi will work to make care globally accessible at home and the office, and to advance cure. LifeNome: is a B2B2C precision health platform powered by genomics and AI, offering personalized health and well-being solutions to the world's leading enterprises. LG and LifeNome plan to bring to market the world’s first precision maternal and family health platform, supporting pregnant individuals 24/7 from conception all the way to the early stages of a child's life. Mindset Medical: is a sensor-based technology platform that can use a camera in patient-owned devices to virtually capture health and biological readings to assist doctors in enhancing medical diagnosis and treatment effectiveness. Expanding upon new services available to doctors and providers, LG’s work with Mindset Medical is expected to make it easier for medical providers to understand patient health over time or during live virtual doctor visits. XRHealth: develops virtual treatment rooms, integrating immersive VR/AR technology, licensed clinicians and real-time data analytics on one platform, providing a comprehensive therapeutic care solution for patients through the continuum of care, from the hospital to the patient’s home. LG and XRHealth will continue to grow the service offering to deliver more insights to clinicians and enable more precise personalized care. Electric Mobility – With LG’s commitment to sustainability as an organization, LG NOVA is working to pursue new opportunities to expand access to electric vehicle (EV) and electric mobility solutions by enabling more businesses to leverage their infrastructure to provide EV services. Driivz: empowers major EV service providers with an end-to-end EV charging and smart energy management software platform. LG and Driivz will work together to enable the hospitality industry across the United States to offer EV charging-as-a-service, while optimizing their EV charging operations and providing their customers with an exceptional EV charging experience. I-EMS Solutions, Ltd. uses innovative AI and blockchain-based distributed energy resource management systems (DERMS) and transactive energy software platforms to enable power optimization across smart cities, smart homes, and e-mobility. By working with I-EMS, LG will help modernize the electricity grid and optimize energy management to deliver better power management solutions for the market. SparkCharge: offers an affordable and convenient way for electric vehicle owners to charge their EVs without a direct-access charger at home or on the road. LG and SparkCharge plan to work together to deliver turnkey EV solutions for businesses to create a stream of revenue from their parking spaces. The Metaverse – The Metaverse will bring greater capabilities that will change how we engage across the digital space in the future. LG is looking to broaden its role and explore new services and applications for enterprises that leverage the capabilities of the Metaverse. iQ3 Connect: provides immersive 3D workspace technology to enable distributed teams to cost-effectively work, collaborate and train from anywhere, on any AR, VR, or 2D device. LG will work with iQ3 Connect to deploy immersive training and realtime collaborative workspace solutions for enterprises. NeuroTrainer: is a brain training and optimization platform deployed in VR to create immersive environments and training protocols that utilizes the scientific principles of neuroplasticity to enhance focus and cognitive performance. Expanding upon iQ3 capabilities, LG and NeuroTrainer will work together to add platform capabilities and enhancements designed to further refine NeuroTrainer as a powerful tool for corporate wellness and mental resiliency. LG NOVA’s second annual Mission for The Future (2022) is now open for submissions. Deadline to submit is Thursday, Oct. 6, 2022. Please visit www.lgnova.com/mission22 for more information on how to submit new ideas to LG NOVA. *Subject to due diligence and other considerations. # # # About LG NOVA LG NOVA, the North American Innovation Center for global innovation leader LG Electronics, is a team focused on bringing innovation from the outside to LG. LG NOVA is based in Santa Clara, Calif. The center's mission is to build, nurture and grow innovations that impact the future. Learn more about LG NOVA at www.lgnova.com. About LG Electronics USA: LG Electronics USA, Inc., based in Englewood Cliffs, N.J., is the North American subsidiary of LG Electronics, Inc., a $63 billion global innovator in technology and manufacturing. In the United States, LG sells a wide range of innovative home appliances, home entertainment products, commercial displays, air conditioning systems, energy solutions and vehicle components. LG is 2022 ENERGY STAR® Partner of the Year-Sustained Excellence. The company’s commitment to environmental sustainability and its “Life’s Good” marketing theme encompass how LG is dedicated to people’s happiness by exceeding expectations today and tomorrow.

Aniiket Sengar
07 September, 2022
pin

Novo Nordisk to explore obesity risk tests with Digbi Health pilot project

Novo Nordisk will begin a pilot project to evaluate how genomic and microbiome-based tests can be used to help prevent obesity. The work is part of a tie-up with Digbi Health and comes as Novo’s Wegovy franchise is expected to keep up its quick growth. The obesity medication was approved in June 2021. Earlier this year, the drugmaker doubled its revenue target for Wegovy, saying it expects to bring in more than $3.7 billion in sales by 2025. By working with Digbi and the startup’s digital screening offerings, the pilot will explore how a person’s genes, proteins, gut bacteria and lifestyle data can help predict whether they have a high or low risk of obesity as well as the range of cardiac and metabolic conditions that may come with it. Obesity-related risks vary significantly by gender and ancestry, and, according to the companies, most weight management programs do not incorporate information from genetics or the gut microbiome. As part of the pilot, Digbi—which offers diagnostic tests and artificial-intelligence-powered coaching programs—has enrolled in Novo Nordisk’s Global Prevention Accelerator Program, which launched last year with a special focus on worldwide obesity. With funding from the Big Pharma, Digbi aims to show its digital care offerings can scale up to reach large numbers of people while also being adaptable for local populations. The companies said they plan to complete the initial steps of the pilot by the end of September before expanding Digbi’s platform to demonstrate large-scale validation through the help of Digbi’s user base. Novo’s accelerator had previously selected Ksana Health, developer of the remote measurement platform Vira, to offer an objective system for tracking behavior patterns and forming personalized care plans. The Danish drugmaker also expanded its research into obesity this year through a collaboration with EraCal Therapeutics, a Swiss biotech that is developing new treatments aimed at food intake regulation, suppressing appetite and other characteristics of metabolism. Also known as semaglutide, Novo Nordisk’s Wegovy was first approved for treating diabetes. It received a new green light in obesity alongside diet and exercise last year based on phase 3 trial data showing it helped one-third of treated patients lose more than 20% of their body weight over about a year and a half. Patients without Type 2 diabetes lost 17% to 18% of their weight on average.

Aniiket Sengar
22 August, 2022

Contact Us

Have any questions? Please feel free
to reach out and contact us

Email

Powered by science

We know why you’re here. You saw the word “science” and your heart took a little extra beat, didn’t it? you’re the patient who prints out articles to take to your doctor’s office. You scour the latest studies for the newest developments in nutrition, weight loss, and fitness.